Amneal Will Go After 505(b)(2) Opportunity Under Patels’ Leadership

 
• By Aidan Fry
  
Hybrid
Hybrid 505(b)(2) drugs are a key part of Amneal's plans to revive its fortunes under new management • Source: Shutterstock

More from Value Added Medicines

More from Products